Clinical Trials Browser

Phase 1/2 × INDUSTRY × tepotinib × Clear all

NCT04739358 2023-10-18

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01988493 2022-08-24

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Phase 1/2 Completed

117 enrolled 30 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02115373 2022-08-24

c-Met Second-Line Hepatocellular Carcinoma

Phase 1/2 Completed

66 enrolled 34 charts

Gastrointestinal

Carcinoma, Hepatocellular